 HOUSTON, Sept. 07, 2022 GLOBE NEWSWIRE -- Alaunos Therapeutics, Inc. Alaunos or the Company Nasdaq: TCRT, a clinical-stage oncology-focused cell therapy company, today announced Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.D., Vice President, Research Development will be participating in the following upcoming investor conferences. 